The interferon story continues: EORTC CLTG study explores pegylated interferon α-2a's role in treating mycosis fungoides/Sézary syndrome

被引：0
|
作者：
Stadler, Rudolf [1 ]
机构：
[1] Ruhr Univ Bochum, Skin Canc Ctr, Univ Dept Dermatol Venereol Allergol & Phlebol, Johannes Wesling Med Ctr Minden,UKRUB, Minden, Germany
来源：
BRITISH JOURNAL OF DERMATOLOGY | 2024年 / 191卷 / 03期
关键词：
D O I：
10.1093/bjd/ljae188
中图分类号：
R75 [皮肤病学与性病学];
学科分类号：
100206 ;
摘要：
引用
收藏
页码：321 / 322
页数：2
相关论文
共 24 条
  • [1] Real-world study of pegylated interferon α-2a to treat mycosis fungoides/Sézary syndrome using time to next treatment as a measure of clinical benefit: an EORTC CLTG study
    Mitsunaga, Keila
    Bagot, Martine
    Ram-Wolff, Caroline
    Guenova, Emmanuella
    von Gugelberg, Christina
    Hodak, Emmilia
    Amitay-Laish, Iris
    Papadavid, Evangelia
    Jonak, Constanze
    Porkert, Stefanie
    Scarisbrick, Julia
    Applewaite, Rona
    Beylot-Barry, Marie
    Nicolay, Jan
    Quaglino, Pietro
    Sanches, Jose Antonio
    Cury-Martins, Jade
    Lora-Pablos, David
    Ortiz, Pablo
    BRITISH JOURNAL OF DERMATOLOGY, 2024, 191 (03) : 419 - 427
  • [2] Increased expression of squamous cell carcinoma antigen 1 and 2 in mycosis fungoides and Sézary syndrome
    Kenta Oka
    Takuya Miyagawa
    Hiraku Suga
    Tomomitsu Miyagaki
    Yuka Mizuno
    Hiroaki Kamijo
    Teruyoshi Hisamoto
    Issei Omori
    Hikari Boki
    Tomonori Oka
    Naomi Takahashi-Shishido
    Makoto Sugaya
    Shinichi Sato
    European Journal of Dermatology, 2022, 32 : 464 - 470
  • [3] Genomic analysis of mycosis fungoides and Sézary syndrome identifies recurrent alterations in TNFR2
    Alexander Ungewickell
    Aparna Bhaduri
    Eon Rios
    Jason Reuter
    Carolyn S Lee
    Angela Mah
    Ashley Zehnder
    Robert Ohgami
    Shashikant Kulkarni
    Randall Armstrong
    Wen-Kai Weng
    Dita Gratzinger
    Mahkam Tavallaee
    Alain Rook
    Michael Snyder
    Youn Kim
    Paul A Khavari
    Nature Genetics, 2015, 47 : 1056 - 1060
  • [4] Racial Disparities in Mycosis Fungoides/Sézary Syndrome-A Single-Center Observational Study of 292 Patients
    Gandham, Ashley R.
    Geller, Shamir
    Dusza, Stephen W.
    Kupper, Thomas S.
    Myskowski, Patricia. L.
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2024, 24 (04): : e174 - e180
  • [5] Predictive and Prognostic Biomarkers in Patients With Mycosis Fungoides and Sézary Syndrome (BIO-MUSE): Protocol for a Translational Study
    Belfrage, Emma
    Sara, E. K.
    Johansson, Asa
    Brauner, Hanna
    Sonesson, Andreas
    Drott, Kristina
    JMIR RESEARCH PROTOCOLS, 2024, 13
  • [6] Mycosis fungoides and Sézary syndrome: a population-wide study on prevalence and health care use in Finland in 1998–2016
    Jaana Keto
    Sonja Hahtola
    Miika Linna
    Liisa Väkevä
    BMC Health Services Research, 21
  • [7] Management experience of advanced-stage mycosis fungoides/Sézary syndrome: a retrospective study from Spanish haematology referral units
    Silvana Novelli
    Alejandro Martín
    Jose Javier Sánchez
    Manuel Espeso
    Anna Mozos
    Javier Briones
    European Journal of Dermatology, 2020, 30 : 397 - 403
  • [8] Treatment of ocular symptoms of Behcet's disease with interferon α2a:: a pilot study
    Kötter, I
    Eckstein, AK
    Stübiger, N
    Zierhut, M
    BRITISH JOURNAL OF OPHTHALMOLOGY, 1998, 82 (05) : 488 - 494
  • [9] Concurrent Autoimmune Hepatitis and Grave's Disease in Hepatitis C during Pegylated Interferon α-2a and Ribavirin Therapy
    Trikudanathan, Guru V.
    Ahmad, Imad
    Israel, Jonathan L.
    SAUDI JOURNAL OF GASTROENTEROLOGY, 2011, 17 (05): : 348 - 352
  • [10] Clinical characteristics, initial treatment, and prognosis of mycosis fungoides and Sézary syndrome: A retrospective, single-center study at the Centre Hospitalier Universitaire of Quebec
    Lachance, M.
    Thibeault, M-M
    ANNALES DE DERMATOLOGIE ET DE VENEREOLOGIE, 2023, 150 (04): : 276 - 280
123